Federman, N., Ulmert, H. D. S., Czernin, J., Singh, A. S., Altai, M., Turpin, B., Trucco, M. M., VanHeyst, K., Hoogstra, D. J., Tine, B. A. V., Rudoltz, M. S., Wang, C., Anand, A., Shulman, D. S. (2026). A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRRC15-targeted
                    <sup>177</sup>
                    lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps11587